Marketing and confidentiality
When potentially valuable technology has been identified and protected, Oxford University Innovation works closely with the inventors to commercialise the technology. This involves identifying the right partner for the commercial development and exploitation of the technology in the marketplace.
It is easy to choose the wrong partner and a number of considerations should be addressed when choosing partner(s). This includes:
sufficient resources to take the technology to market
real intent to develop the technology as it may compete with in-house programmes
awareness of access of the final products, where applicable, to developing countries
The last point, involving partly ethical concerns, is of particular relevance to human healthcare technologies and researchers should discuss with us appropriate measures which can be taken.
Oxford University Innovation will write a one page, non-confidential, summary of the invention in conjunction with the inventor which is initially distributed to the members of the Oxford University Innovation Society, a group of leading industrial companies and potential investors.
One month after launching the technology to the Oxford University Innovation Society, we then contact other potential licensees and publish the opportunity on our website. We actively encourage networking between potential licensees and researchers, and we welcome commercial leads from researchers.
Following expressions of interest from companies, we will arrange meetings to discuss possible commercial transactions with a view to entering into option, evaluation or licensing arrangements. Such arrangements may also involve the funding of further research in the researchers’ laboratory.
Access to essential medicines
The University of Oxford and Oxford University Innovation are mindful of the importance of development and distribution of new health-related technologies for less developed countries.
The University’s policy when licensing its technology for commercial exploitation purposes is, as far as is practicable, to:
prosecute patent applications in less developed countries only as necessary (for example, to provide development and marketing leverage for new products, or to exert leverage over global licensees)
grant licences with provisions that seek to increase the availability of medicines at affordable prices to less developed countries
The University expects its commercial licensing partners to appreciate and cooperate with this policy.
Unless published for academic reasons, it is very important that researchers do not discuss their inventions with third parties without the protection of a confidentiality (or non-disclosure) agreement (available from us). This is the case even when a patent application has been filed.
Outline or selected information about the technology is possibly of value to companies and can be obtained by companies from preliminary discussions with researchers.
Confidentiality agreements are necessary when you wish to disclose confidential information to a company in the early stages of discussions which may lead to research collaboration, or licensing of intellectual property.
Keeping information confidential until it can be protected is often essential in establishing links with industry. It is far harder to encourage a company to fund research or to licence technology if the company has no privileged or exclusive access to the research work.